Drug Candidate Repairs Motor/Sensory Function in Stroke
Source: Streetwise Reports  (7/29/22)
Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair to damage from ischemic stroke seven days following the event. More >

Additional Study Review Reveals Patients Coughed Much Less
Source: Streetwise Reports  (7/28/22)
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought. More >

Biotech Co. Granted New Patent for Breast Cancer Vaccine
  (7/27/22)
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa. More >

Biopharma Co. Signs Exclusive License Deal for Ricin Antigen
Source: Streetwise Reports  (7/27/22)
Shares of Soligenix Inc. traded 8% higher after the company reported it formed a strategic global partnership to supply SERB Pharmaceuticals with its novel ricin antigen for use in developing a therapeutic treatment against ricin poisoning. More >

Biomedical Firms Merger Makes Programming Cells Easier
Source: Streetwise Reports  (7/26/22)
Shares of Zymergen Inc. traded 16% higher after the company reported it agreed to be acquired by Ginkgo Bioworks Inc. in an all-stock transaction valued at $300 million. More >

Cancer Co.'s Price Target Adjusted After Reverse Stock Split
  (7/25/22)
Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share. More >

Radiotherapy Co. On-Track With Two Clinical Trials
  (7/24/22)
Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22. More >

Pro Athlete Benefits From Co.'s Wound Treatment Device
Source: Streetwise Reports  (7/22/22)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system. More >

Medical Device Firm Maintains Growth Momentum in Q2/22
  (7/21/22)
electroCore Inc.'s Q2/22 and H1/22 revenues are up quarter over quarter and year over year, respectively, and the upward trend is expected to continue through year-end 2022, noted an H.C. Wainwright & Co. report. More >

Amazon Makes $3.9B Bid for Virtual Primary Care Co.
Source: Streetwise Reports  (7/21/22)
Shares of One Medical traded nearly 70% higher after the company reported it agreed to be acquired by Amazon Inc. for $18.00 per share in an all-cash deal valued at $3.9 billion. More >

Biotech Co.'s Phase 3 Trial First to Get Grant
Source: Streetwise Reports  (7/20/22)
A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat alcohol use disorder. It could be a catalyst for the share price. More >

Drug Repurposing Co. Provides Opportunity for High Rewards
  (7/20/22)
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company. More >

Trial Results Show New Drug Improves Dry Eye Symptoms
Source: Matthew Caufield   (7/19/22)
These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Looks to Expand New Drug Label Down the Road
  (7/18/22)
ScPharmaceuticals Inc. just released topline results from a Phase 2 pilot study supporting the drug developer that is pursuing the expansion of its new drug label, noted an H.C. Wainwright & Co. report. More >

Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’
Source: Patrick Trucchio  (7/15/22)
Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with alcohol use disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD. More >

Pharma Co. Reduces Mortality Rates by 70% in ALS Trial
Source: Streetwise Reports  (7/15/22)
Shares of Clene Inc. traded 38% higher yesterday after the company reported that its CNM-Au8 was shown to significantly decrease mortality in its RESCUE-ALS long-term extension trial. More >

Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry
Source: Jason McCarthy  (7/14/22)
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report. More >

Biopharma Co. Posts 17% BMI Reduction in Ph. 2 Trial
Source: Streetwise Reports  (7/14/22)
Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its Phase 2 clinical study of setmelanotide in hypothalamic obesity. The data shows that after 16 weeks of treatment with setmelanotide, patients experienced a 17.2% mean reduction in BMI and a mean weight loss of 15.8%. More >

Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.
Source: Andrew Partheniou  (7/13/22)
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments. More >

Three Analysts Like Healthcare Co.'s Upside
Source: Streetwise Reports  (7/11/22)
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care. More >

Pharma Looks To Improve Potential Psychedelic Stroke Drug
Source: Streetwise Reports  (7/11/22)
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September. More >

New Drug Is Shown to Help Stopped or Reduced Bile Flow
  (7/10/22)
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report. More >

New DMD Drug Yields 'Compelling' Data
  (7/9/22)
A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report. More >

Amended Agreement to Benefit Two Biotech Firms
  (7/8/22)
In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report. More >

Co. Makes Financing Deals Around Two of Its Approved Drugs
  (7/7/22)
The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report. More >